Drugs / Uroffollitropin
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05362799 Comparator | Jun 2022 → Dec 2023 | female infertility | Menoufia University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Uroffollitropin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05362799 ↗ |
| Known as | Fostimon | “highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days.” NCT05362799 ↗ |
| Route | Intramuscular | “at a dose of 75IU S.C or IM” NCT05362799 ↗ |
| Route | Subcutaneous | “at a dose of 75IU S.C or IM” NCT05362799 ↗ |